+264.7%
APP vs MRNA
-27.3%
+292.0%
-90.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -8.1% | -2.2% | -5.9% | -7.9% |
| 7D | -14.9% | -12.7% | -2.2% | -13.8% |
| 30D | +30.0% | -20.7% | +50.7% | +32.4% |
| 3M | +12.8% | +46.3% | -33.5% | +8.3% |
| 6M | -27.8% | +305.2% | -333.0% | -44.4% |
| YTD | -48.3% | +561.2% | -609.6% | -65.1% |
| 1Y | -33.1% | +772.1% | -805.2% | -57.8% |
| 3Y | +781.7% | +147.0% | +634.8% | +571.8% |
| All | +264.7% | -27.3% | +292.0% | +260.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling